These highlights do not include all the information needed to use North American Coral Snake Antivenin (Equine) safely and effectively. See full prescribing information for North American Coral Snake Antivenin (Equine).
North American Coral Snake Antivenin (Equine) Lyophilized Powder for Solution for Intravenous Injection Initial U.S. Approval: 1967
INDICATIONS AND USAGE
North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snakes - Micrurus. (1)
DOSAGE AND ADMINISTRATION
For intravenous use only.
In adults and adolescents, the dose may vary from 3 to 5 vials, depending on the response to treatment. (2.1)
In small children, the dose may be decreased, depending on the response to treatment. (2.1)
Contents of each reconstituted vial can neutralize approximately 250 mouse (Lethal Dose) LD50 or approximately 2 mg of M. fulvius venom. (2.1)
Infuse the first 1 or 2 mL over a 3- to 5-minute period, observing for allergic reaction. If tolerated, administer the rest of the dose at the rate that is comfortable for the patient based on body weight and general condition. Do not exceed 4 mL per minute for children. (2.2)
DOSAGE FORMS AND STRENGTHS
Lyophilized powder in single use vial for reconstitution for injection. (3)
CONTRAINDICATIONS
Do not administer North American Coral Snake Antivenin (Equine) prophylactically to asymptomatic patients. (4)
Do not use in patients with a known history of hypersensitivity to horse serum unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available. (4)
WARNINGS AND PRECAUTIONS
Patients sensitive to North American Coral Snake Antivenin (Equine) or horse serum may develop anaphylaxis. Prior to intravenous North American Coral Snake Antivenin (Equine) administration consider performing a proper skin test and modify therapy if indicated. (5.1)
ADVERSE REACTIONS
Adverse reactions may include anaphylaxis and serum sickness, vomiting, and abdominal pain. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION.
Revised: 7/2019
Find ANTIVENIN® medical information:
Find ANTIVENIN® medical information:
Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
ANTIVENIN® Quick Finder
Medication Guide
Health Professional Information
Highlights
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use North American Coral Snake Antivenin (Equine) safely and effectively. See full prescribing information for North American Coral Snake Antivenin (Equine).
North American Coral Snake Antivenin (Equine) Lyophilized Powder for Solution for Intravenous Injection Initial U.S. Approval: 1967
INDICATIONS AND USAGE
North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snakes - Micrurus. (1)
DOSAGE AND ADMINISTRATION
For intravenous use only.
In adults and adolescents, the dose may vary from 3 to 5 vials, depending on the response to treatment. (2.1)
In small children, the dose may be decreased, depending on the response to treatment. (2.1)
Contents of each reconstituted vial can neutralize approximately 250 mouse (Lethal Dose) LD50 or approximately 2 mg of M. fulvius venom. (2.1)
Infuse the first 1 or 2 mL over a 3- to 5-minute period, observing for allergic reaction. If tolerated, administer the rest of the dose at the rate that is comfortable for the patient based on body weight and general condition. Do not exceed 4 mL per minute for children. (2.2)
DOSAGE FORMS AND STRENGTHS
Lyophilized powder in single use vial for reconstitution for injection. (3)
CONTRAINDICATIONS
Do not administer North American Coral Snake Antivenin (Equine) prophylactically to asymptomatic patients. (4)
Do not use in patients with a known history of hypersensitivity to horse serum unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available. (4)
WARNINGS AND PRECAUTIONS
Patients sensitive to North American Coral Snake Antivenin (Equine) or horse serum may develop anaphylaxis. Prior to intravenous North American Coral Snake Antivenin (Equine) administration consider performing a proper skin test and modify therapy if indicated. (5.1)
ADVERSE REACTIONS
Adverse reactions may include anaphylaxis and serum sickness, vomiting, and abdominal pain. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
These highlights do not include all the information needed to use North American Coral Snake Antivenin (Equine) safely and effectively. See full prescribing information for North American Coral Snake Antivenin (Equine).
North American Coral Snake Antivenin (Equine) Lyophilized Powder for Solution for Intravenous Injection Initial U.S. Approval: 1967
INDICATIONS AND USAGE
North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snakes - Micrurus. (1)
DOSAGE AND ADMINISTRATION
For intravenous use only.
In adults and adolescents, the dose may vary from 3 to 5 vials, depending on the response to treatment. (2.1)
In small children, the dose may be decreased, depending on the response to treatment. (2.1)
Contents of each reconstituted vial can neutralize approximately 250 mouse (Lethal Dose) LD50 or approximately 2 mg of M. fulvius venom. (2.1)
Infuse the first 1 or 2 mL over a 3- to 5-minute period, observing for allergic reaction. If tolerated, administer the rest of the dose at the rate that is comfortable for the patient based on body weight and general condition. Do not exceed 4 mL per minute for children. (2.2)
DOSAGE FORMS AND STRENGTHS
Lyophilized powder in single use vial for reconstitution for injection. (3)
CONTRAINDICATIONS
Do not administer North American Coral Snake Antivenin (Equine) prophylactically to asymptomatic patients. (4)
Do not use in patients with a known history of hypersensitivity to horse serum unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available. (4)
WARNINGS AND PRECAUTIONS
Patients sensitive to North American Coral Snake Antivenin (Equine) or horse serum may develop anaphylaxis. Prior to intravenous North American Coral Snake Antivenin (Equine) administration consider performing a proper skin test and modify therapy if indicated. (5.1)
ADVERSE REACTIONS
Adverse reactions may include anaphylaxis and serum sickness, vomiting, and abdominal pain. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION.
Revised: 7/2019
Resources
Didn’t find what you were looking for?
Contact us.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are
not part of a clinical trial* for this product, click the link below to submit your
information:
*If you are involved in a clinical trial for this product, adverse
events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related
to a different Pfizer product, please call Pfizer Safety at
(800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report
adverse events or product quality concerns either online at
www.fda.gov/medwatch or
call
(800) 822-7967.